---
title: "Novo Nordisk Copenhagen stock price (NOVOB.DC) closed down 1.81%, at 308.80 Danish Krone, with a cum"
description: "Novo Nordisk Copenhagen stock price (NOVOB.DC) closed down 1.81%, at 308.80 Danish Krone, with a cumulative decline of 31.70% this week, marking the company's worst weekly performance since its IPO in"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/251238721.md"
published_at: "2025-08-01T17:40:05.000Z"
---

# Novo Nordisk Copenhagen stock price (NOVOB.DC) closed down 1.81%, at 308.80 Danish Krone, with a cum

> Novo Nordisk Copenhagen stock price (NOVOB.DC) closed down 1.81%, at 308.80 Danish Krone, with a cumulative decline of 31.70% this week, marking the company's worst weekly performance since its IPO in Denmark. At the same time, the company announced the promotion of an internal executive to the new CEO during the earnings report. Additionally, U.S. President Trump has called for pharmaceutical companies to lower drug prices in the U.S. market

Novo Nordisk Copenhagen stock price (NOVOB.DC) closed down 1.81%, at 308.80 DKK, with a cumulative decline of 31.70% this week, marking the company's worst single-week performance since its IPO in Denmark. This week, the company announced the promotion of an internal executive to the new CEO during the earnings report. Subsequently, U.S. President Trump called on numerous pharmaceutical companies to lower drug prices in the U.S. market

### Related Stocks

- [NVO.US - Novo Nordisk AS](https://longbridge.com/en/quote/NVO.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| As the FDA Approves a Wegovy Pill, Should You Buy, Sell, or Hold Novo Nordisk Stock? | As the FDA Approves a Wegovy Pill, Should You Buy, Sell, or Hold Novo Nordisk Stock? | [Link](https://longbridge.com/en/news/270794581.md) |
| Novo Nordisk (NVO) Rethinks Pricing as Compounded GLP-1 Drugs Gain Ground | Novo Nordisk CEO Mike Doustdar announced that 1.5 million people in the U.S. are using compounded GLP-1 weight-loss drug | [Link](https://longbridge.com/en/news/272307926.md) |
| Palantir spent $25M on CEO flights so Alex Karp could do all the talking | Palantir CEO Alex Karp has spent nearly $25 million on private flights over two years to maintain his visibility in the  | [Link](https://longbridge.com/en/news/276359392.md) |
| BUZZ-Street View: Booking Holdings may be shielded from AI disruption noise | Booking Holdingssurpassed Q4 profit expectations, driven by strong international travel demand. RBC Capital Markets sugg | [Link](https://longbridge.com/en/news/276333390.md) |
| BREAKINGVIEWS-Software CEO wallets can help ease AI overkill | Software CEOs can mitigate the impact of AI-related stock declines by purchasing shares with their own funds, as seen wi | [Link](https://longbridge.com/en/news/276327967.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.